The phrase "a source of tumor" is not correct in standard English; it should be "a source of tumors." You can use it when discussing factors that contribute to the development of tumors in a medical or scientific context.
Example: "Certain environmental factors can act as a source of tumors in susceptible individuals."
Alternatives: "a cause of tumors" or "a contributor to tumor formation."
CRCL provides both a source of tumor antigens and danger signals leading to dendritic cell activation.
The use of allogeneic cells as a source of tumor antigen could increase the clinical applicability of this therapy, so we investigated the efficacy of DC loaded with apoptotic, allogeneic cells in this model.
In this regard, CTCs hold significant promise as a source of tumor material to facilitate clinical biomarker evaluation.
In conclusion, our study demonstrates that, allogeneic iPSC transplantation into the heart can cause in situ tumorigenesis in immunocompetent recipients, and that the cells leaked from the beating heart likely serve as a source of tumor spread.
The use of these markers in plasma as a source of tumor information would be important, since they are obtained by a non-invasive method that would be useful during patients' follow-up and treatment monitoring.
Circulating tumor cells thus have tremendous potential to change our approach to biomarker evaluation by providing a source of tumor material that is easily accessible through a blood draw.
Indeed, these mechanisms are linked, because uncontrolled local disease may serve as a source of systemic tumor reseeding.
Autophagosomes from cancer cells are a source of specific tumor-associated antigens, and autophagosome-enriched and autophagosome-based vaccines have potent antitumor efficacy.
It is a rich source of tumor cell-derived proteins, thereby, representing a wide array of potential biomarkers.
Our study demonstrates that allogeneic iPSC transplantation in the heart will likely result in in situ tumorigenesis, and that cells leaked from the beating heart are a potential source of tumor spread, underscoring the importance of evaluating the safety of future iPSC therapy for cardiac disease.
In addition, tumor-exosomes can provide a reliable source of tumor antigens in tumors where immunogenic entities are unknown.
